APA (7th ed.) Citation

KD, M., A, T., S, A., Y, Z., E, C., R, B., . . . FV, R. (2026). A phase 1 study of ASTX727 plus talazoparib in patients with triple-negative or hormone resistant/HER2-negative metastatic breast cancer. Cancer, 132(8), e70407. https://doi.org/10.1002/cncr.70407

Chicago Style (17th ed.) Citation

KD, Miller, et al. "A Phase 1 Study of ASTX727 Plus Talazoparib in Patients with Triple-negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer." Cancer 132, no. 8 (2026): e70407. https://doi.org/10.1002/cncr.70407.

MLA (9th ed.) Citation

KD, Miller, et al. "A Phase 1 Study of ASTX727 Plus Talazoparib in Patients with Triple-negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer." Cancer, vol. 132, no. 8, 2026, p. e70407, https://doi.org/10.1002/cncr.70407.